Patients were randomized to receive either hCG or recombinant human LH as a trigger of oocyte maturation ( 5,000 IU ) and for luteal phase support ( 5,000 IU , 2,500 IU , and 2,500 IU on the day of follicular aspiration , 2 days later , and 5 days later , respectively ) .
